February 4, 2022
RFA-AI-21-079 - Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
National Institute of Allergy and Infectious Diseases (NIAID)
This Notice informs potential applicants of a revision to the Eligibility Information in Funding Opportunity Announcement (FOA) RFA-AI-21-079, "Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)".
Effective immediately, the following section of RFA-AI-21-079 has been modified, as indicated below.
Currently Reads:
Section III. Eligibility Information
3. Additional Information on Eligibility
Number of Applications
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.
The NIH will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
Modified to Read (changes shown in bold italics):
Section III. Eligibility Information
3. Additional Information on Eligibility
Number of Applications
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.
NIAID will not accept applications from institutions that are currently funded under the previous version of this FOA,Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional), RFA-AI-20-007.
The NIH will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
All other aspects of the FOA remain the same.
Gang Dong, MD, PhD
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3508
Email: gdong@niaid.nih.gov